Compare DTST & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTST | INTS |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 24.0M |
| IPO Year | N/A | 2023 |
| Metric | DTST | INTS |
|---|---|---|
| Price | $5.07 | $0.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $4.33 |
| AVG Volume (30 Days) | 131.9K | ★ 3.1M |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8036.56 | N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $25,529,819.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.32 | ★ N/A |
| Revenue Growth | ★ 260.19 | N/A |
| 52 Week Low | $2.93 | $0.19 |
| 52 Week High | $5.44 | $3.17 |
| Indicator | DTST | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 76.59 | 45.52 |
| Support Level | $5.03 | $0.37 |
| Resistance Level | $5.07 | $0.43 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 98.11 | 13.19 |
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.